Alexion Pharmaceuticals, Inc.NASDAQ
Advanced Chart
  • Fri, Nov. 18, 11:13 AM
    • Barron's Ben Levisohn reports that Gilead Sciences (GILD -1.3%) has a range of attractive candidates should it decide to spend some its $32B cash hoard on an acquisition, a virtual certainty after the recent momelotinib disappointment.
    • Considering the company's stated interest in oncology, obvious choices are Incyte (INCY -1.1%) and TESARO (TSRO -3%).
    • Venturing out into the rare disease space, Alexion Pharmaceuticals (ALXN -1.6%), Vertex Pharmaceuticals (VRTX -1.6%) and BioMarin Pharmaceutical (BMRN -1.1%) are attractive fare.
    • None of these companies are a surprise to biotech followers. All have been noted as buyout targets for some time now.
    | Fri, Nov. 18, 11:13 AM | 36 Comments
  • Sep. 9, 2015, 9:33 AM
    • Epirus Biopharmaceuticals (NASDAQ:EPRS) acquires privately-held Netherlands-based Bioceros for $14.1M in cash and stock payable over a one-year period.
    • Bioceros develops monoclonal antibodies and GMP-ready cell lines. It has a number of biosimilar cell lines from its proprietary CHO platform.
    • The deal enables Epirus to pick up three preclinical product candidates: BOW080 [biosimilar to Alexion Pharmaceuticals' (NASDAQ:ALXN) Soliris (eculizumab)]; BOW100 [biosimilar to J&J's (NYSE:JNJ) Simponi (golimumab)] and BOW090 [biosimilar to J&J's Stelara (ustekinumab)].
    | Sep. 9, 2015, 9:33 AM | 1 Comment
  • Aug. 18, 2015, 8:28 AM
    • Celsus Therapeutics (NASDAQ:CLTX) secures a $75M private placement of securities with select institutional investors. The transaction is subject the shareholder approval in conjunction with the company's proposed acquisition of Volution Immuno Pharmaceuticals. The vote is scheduled for September 16 at Celsus's General Shareholder Meeting. Closing date is projected to be September 18.
    • The company expects to receive net proceeds of ~$70M from the sale of American Depository Shares (ADSs). Each ADS represents 10 ordinary shares. Based on yesterday's ADS closing price of $0.61 and assuming an aggregate of 949,410,450 fully-diluted shares following the close of the  acquisition, each ADS would be priced at $1.58.
    • On a pro forma basis, prior to the effect of the private placement, current Celsus shareholders will own ~8.32% of the combined entity while Volution security holders will own ~91.68%. The private placement values the combination, which will be renamed Akari Therapeutics and trade under the symbol "AKTX," at $150M.
    • Net proceeds will fund the clinical development of Coversin, a C5 inhibitor for the treatment of complement-related disorders in hematology, nephrology and neurology, working capital and general corporate purposes. C5 inhibition was commercially pioneered by Alexion Pharmaceuticals (NASDAQ:ALXN) with Soliris (eculizumab).
    | Aug. 18, 2015, 8:28 AM
  • Jun. 11, 2015, 7:59 AM
    • RBC Capital Markets' Michael Yee says (NASDAQ:DYAX) would be a juicy acquisition for the likes of Sanofi (NYSE:SNY), Alexion Pharmaceuticals (NASDAQ:ALXN) or BioMarin Pharmaceutical (NASDAQ:BMRN). He thinks the takeout price could be as high as $39 per share or 59% above yesterday's close of $24.53.
    • Dyax's allure pertains to its investigational drug for hereditary angioedema (HAE), Fast Track-designated DX-2930, which has performed well in early-stage studies. The only approved therapy for HAE is Shire's (NASDAQ:SHPG) Cinryze [C1 esterase inhibitor (human)] which costs as much as $630K per year. Its on track to be Shire's #2 seller in two years.
    • Previously: Dyax +39.1% on positive DX-2930 trial results (March 31)
    • Previously: Dyax scores Orphan designation for HAE treatment (Dec. 5, 2013)
    | Jun. 11, 2015, 7:59 AM
  • May 6, 2015, 1:29 PM
    • Alexion Pharmaceuticals (ALXN -9.7%) heads south on a 7x surge in volume as investors adjust to the dilution from its $8.4B takeout of Synageva BioPharma (GEVA +113.7%).
    • In addition to $115 in cash, Alexion is offering 0.6581 shares of ALXN stock for each GEVA share. This represents a ~12% dilution to current ALXN shareholders.
    • Here's the math: 0.6581 x 36.5M shares of GEVA = ~24M/202M shares of ALXN = ~12%.
    | May 6, 2015, 1:29 PM
  • May 6, 2015, 7:24 AM
    • Alexion Pharmaceuticals (NASDAQ:ALXN) acquires Synageva BioPharma (NASDAQ:GEVA) for $115 in cash and 0.6581 shares of ALXN for each share of GEVA, for a total value of $230 per share or $8.4B.
    • Alexion expects to achieve annual cost synergies this year and growing to at least $150M in 2017. The transaction will be accretive to non-GAAP EPS in 2018.
    • Synageva develops therapies for rare diseases. Its lead product candidate is the Orphan Drug-, Fast Track- and Breakthrough Therapy-designated Kanuma (sebelipase alfa), an enzyme replacement therapy for the treatment of lysosomal acid lipase deficiency or Wolman disease. Its marketing applications are currently under review in the U.S. and Europe. Its second product candidate is the Phase 1/2-stage SBC-103, an enzyme replacement therapy for mucopolysaccharidosis IIIB, known as Sanfilippo B syndrome, a rare, inherited lysosomal storage disease. It is designated an Orphan Drug by the FDA and EMA and for Fast Track review by the FDA.
    • GEVA is up 124% premarket.
    | May 6, 2015, 7:24 AM
  • Oct. 23, 2013, 11:47 AM
    • Is Roche (RHHBY +0.4%) really interested in Alexion (ALXN -0.4%) or BioMarin (BMRN +0.1%)? CEO Severin Schwan isn't telling, but he did say at a Paris conference that the company will "go where the science takes it, wherever it is, independent from the size of the patient population," suggesting a move into rare and orphan diseases.
    • Regarding the company's attempt to expand beyond core cancer treatments, Schwan mentioned autoimmune, inflammatory diseases, and neuroscience, noting that in these "three areas naturally [Roche] is a partner of choice for many companies [and] if there was an interesting opportunity outside of those established areas, I would be very open to look at it."
    • More on Roche/ALXN speculation here, and on BMRN chatter here
    | Oct. 23, 2013, 11:47 AM
  • Sep. 19, 2013, 7:35 AM
    • Did the high price tag on Alexion (ALXN) frighten Roche (RHHBY.OB) into looking at other targets? Rumors of a Roche-ALXN deal were played down in July by the likes of Deutsche, Kepler Cheuvreux, and Adam Feuerstein, as it became clear that the price tag (perhaps more than $20B) was simply too much to swallow.
    • Now it appears Roche has its sights on a slightly less expensive target in BioMarin (BMRN) which, as we reminded investors Tuesday, is no stranger to acquisition rumors.
    • DealReporter claims Roche is lining up around $15B in financing for a bid of between $95-105/share for BMRN, valuing the company at between $13.3B and $14.7B.
    • Roche is the world's largest maker of cancer drugs and a deal would give the company BMRN's PARP inhibitor BMN 673 (along with the rest of the pipeline and four commercialized products which together had total revenue of around $140M in Q2).
    • ALXN -0.9% premarket (low volume), BMRN +11% premarket
    | Sep. 19, 2013, 7:35 AM
  • Jul. 16, 2013, 11:17 AM

    Adam Feuerstein sides with those who think a Roche (RHHBY.OB -1.6%) deal for Alexion (ALXN -1.1%) deal is unlikely. Deutsche's EU pharma team and several other analysts are leaning in the same direction, while Cramer, Piper, and others think a deal may materialize. "Price matters," Feuerstein reminds investors, and while "Soliris sounds like an attractive takeover target, the risk is extreme" considering ALXN's $20B valuation.

    | Jul. 16, 2013, 11:17 AM | 1 Comment
  • Jul. 15, 2013, 3:56 PM

    Alexion (ALXN -5.7%) could be worth as much as $208/ share in a takeout, Piper Jaffray thinks (this is the call Jim Cramer was so incredulous about Monday morning). Analyst Ian Somaiya believes investors can expect multiple bids for the company. (previous)

    | Jul. 15, 2013, 3:56 PM
  • Jul. 14, 2013, 1:04 PM
    "Would it make sense from a value accretion point of view? No way," an analyst tells Reuters regarding the possibility that Roche (RHHBY.OB) may bid for Alexion (ALXN). Skepticism seems to be growing regarding the wisdom of the rumored deal as ALXN, at 32 times forward earnings, looks expensive even considering Roche's falling net debt to total assets ratio, Reuters notes.
    | Jul. 14, 2013, 1:04 PM
  • Jul. 12, 2013, 2:29 PM
    More on Roche-Alexion: A deal by Roche (RHHBY.OB) for Alexion Pharmaceuticals (ALXN +13%) would be one of the richest in biotechnology history if it comes off. The main draw for the drug maker is Alexion's Soliris which is a $400K-per-year wonder drug tapped to treat blood diseases.
    | Jul. 12, 2013, 2:29 PM
  • Jul. 12, 2013, 2:09 PM
    Roche (RHHBY.OB) is reported to be putting together funds in order to make a bid for Alexion Pharmaceuticals (ALXN +19%).
    | Jul. 12, 2013, 2:09 PM
  • Dec. 28, 2011, 4:32 PM

    Alexion Pharmaceuticals (ALXN) agrees to buy privately-held biotech firm Enobia for $1.08B in cash - with $610M paid up front and the rest after various regulatory and sales milestones are hit. Enobia is focused on therapies treating patients with ultra-rare, life-threatening genetic disorders. Shares -1.3% AH. (PR)

    | Dec. 28, 2011, 4:32 PM